Zacks Research Has Optimistic Outlook of WST Q3 Earnings

West Pharmaceutical Services, Inc. (NYSE:WST) – Stock analysts at Zacks Research raised their Q3 2026 earnings estimates for shares of West Pharmaceutical Services in a research report issued to clients and investors on Thursday, August 13th. Zacks Research analyst Team now forecasts that the medical instruments supplier will post earnings of $2.14 per share for the quarter, up from their prior estimate of $2.10. Zacks Research has a “Hold” rating on the stock. The consensus estimate for West Pharmaceutical Services’ current full-year earnings is $8.94 per share. Zacks Research also issued estimates for West Pharmaceutical Services’ Q4 2026 earnings at $2.24 EPS, FY2026 earnings at $8.88 EPS, Q1 2027 earnings at $2.15 EPS, Q2 2027 earnings at $2.47 EPS, Q3 2027 earnings at $2.36 EPS, Q4 2027 earnings at $2.40 EPS, FY2027 earnings at $9.38 EPS, Q1 2028 earnings at $2.33 EPS, Q2 2028 earnings at $2.83 EPS and FY2028 earnings at $10.74 EPS.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, beating the consensus estimate of $2.08 by $0.29. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The firm had revenue of $872.30 million during the quarter, compared to analyst estimates of $839.98 million. During the same quarter in the prior year, the firm earned $1.84 EPS. The business’s revenue for the quarter was up 13.8% compared to the same quarter last year. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS.

Other analysts have also recently issued reports about the stock. Stephens reissued an “overweight” rating and issued a $360.00 price objective on shares of West Pharmaceutical Services in a research note on Tuesday, June 2nd. Wolfe Research assumed coverage on West Pharmaceutical Services in a report on Monday, June 1st. They issued an “outperform” rating and a $375.00 target price on the stock. Morgan Stanley lifted their price target on West Pharmaceutical Services from $325.00 to $365.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 9th. Citigroup raised their price target on shares of West Pharmaceutical Services from $400.00 to $412.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Finally, Weiss Ratings upgraded West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, West Pharmaceutical Services presently has an average rating of “Moderate Buy” and an average price target of $368.08.

West Pharmaceutical Services Stock Performance

Shares of WST opened at $346.78 on Friday. The business has a 50-day simple moving average of $345.78 and a two-hundred day simple moving average of $295.38. The stock has a market cap of $24.41 billion, a price-to-earnings ratio of 44.40, a PEG ratio of 2.46 and a beta of 1.15. The company has a quick ratio of 2.12, a current ratio of 2.82 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services has a 52 week low of $223.83 and a 52 week high of $386.00.

West Pharmaceutical Services Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th were paid a dividend of $0.22 per share. The ex-dividend date of this dividend was Wednesday, July 29th. This represents a $0.88 dividend on an annualized basis and a yield of 0.3%. West Pharmaceutical Services’s payout ratio is 11.27%.

Institutional Trading of West Pharmaceutical Services

A number of hedge funds and other institutional investors have recently made changes to their positions in WST. BlackRock Inc. purchased a new position in West Pharmaceutical Services in the second quarter worth approximately $2,387,990,000. State Street Corp grew its holdings in shares of West Pharmaceutical Services by 2.1% during the 2nd quarter. State Street Corp now owns 3,271,866 shares of the medical instruments supplier’s stock worth $715,884,000 after purchasing an additional 68,330 shares during the period. Artisan Partners Limited Partnership increased its position in shares of West Pharmaceutical Services by 2.9% during the 4th quarter. Artisan Partners Limited Partnership now owns 2,850,401 shares of the medical instruments supplier’s stock worth $784,259,000 after purchasing an additional 79,481 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in West Pharmaceutical Services in the second quarter valued at about $733,733,000. Finally, Generation Investment Management LLP acquired a new stake in shares of West Pharmaceutical Services during the second quarter valued at about $728,168,000. Institutional investors and hedge funds own 93.90% of the company’s stock.

Key Stories Impacting West Pharmaceutical Services

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Zacks raised several earnings forecasts. Estimates increased for Q3 2026 to $2.14 from $2.10, Q4 2026 to $2.24 from $2.20, FY2026 to $8.88 from $8.50, Q1 2027 to $2.15 from $2.09, Q3 2027 to $2.36 from $2.21, FY2027 to $9.38 from $9.24, and FY2028 to $10.74 from $10.48. These revisions suggest improving expectations for West’s longer-term growth and support the positive earnings case. West Pharmaceutical Services stock information
• Positive Sentiment: The upgrades follow West Pharmaceutical’s recent quarterly performance, when the company exceeded earnings and revenue expectations and raised its 2026 outlook. Faster growth in high-value products, wider margins, and stronger projected earnings have helped reinforce the company’s investment story. WST Q2 beat and raised 2026 outlook
• Neutral Sentiment: Not all revisions were positive: Zacks trimmed Q2 2027 EPS to $2.47 from $2.48, Q4 2027 EPS to $2.40 from $2.47, and Q2 2028 EPS to $2.83 from $2.94. The changes are relatively modest, and Zacks maintained its Hold rating.
• Negative Sentiment: Zacks downgraded WST from “Strong Buy” to “Hold.” The change may weigh on sentiment because it signals that the stock’s expected return has become less compelling after its rally. At approximately $346.78, West trades at about 44 times earnings, leaving limited room for execution or forecast disappointments. Zacks.com
• Negative Sentiment: Although West’s growth, margins, and earnings outlook remain attractive, analysts note that its premium valuation raises the bar for additional gains and increases downside risk if growth slows. Should investors buy WST as HVP growth meets a premium valuation?

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.